shares jumped 2.86% to close at $0.72. About 17,233 shares traded hands on 33 trades for the day, compared with an average daily volume of 
n/a shares out of a total float of 33.64 million. After opening the trading day at $0.75, shares of CytRx Corporation stayed within a range of $0.75 to 
and $0.21 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
CytRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It is also engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release technology.
CytRx Corporation is based out of Los Angeles, CA and has some 4 employees. Its CEO is Steven A. Kriegsman.
For a complete fundamental analysis of CytRx Corporation, check out Equities.com’s Stock Valuation Analysis report for 
Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start
CytRx Corporation is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by  Russell 
Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an 
objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives 
a broad, unbiased look at the small-cap market as a whole.
To get more information on CytRx Corporation and to follow the company’s latest updates, you can visit the company’s profile page here: CYTR’s Profile . For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s 
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com . Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer
